Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toward cell specificity in SCA1.

Sandrine Humbert1, Frédéric Saudou

  • 1UMR 146 CNRS, Institut Curie, Bldg. 110, Centre Universitaire, 91405 Orsay Cedex, France.

Neuron
|June 14, 2002
PubMed
Summary

Transcriptional dysregulation is key in polyglutamine neurodegenerative diseases. This study links RNA polymerase II to PQBP-1, revealing mechanisms behind neuronal death selectivity in Spinocerebellar Ataxia type 1.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal cortical development sets the stage in Huntington disease.

Journal of Huntington's disease·2026
Same author

Nanoscale Activity Mapping of Chloride-Permeable Pentameric Receptors.

ACS sensors·2026
Same author

Structure of the Huntingtin F-actin complex reveals its role in cytoskeleton organization.

Science advances·2025
Same author

ACLY links mutant α-synuclein to metabolism, autophagy and neurodegeneration.

Neuron·2025
Same author

CAG repeat mosaicism is gene specific in spinocerebellar ataxias.

American journal of human genetics·2024
Same author

Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.

Journal of Huntington's disease·2024

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Transcriptional dysregulation is a unifying mechanism in polyglutamine (polyQ) neurodegenerative disorders like Spinocerebellar Ataxias (SCAs) and Huntington's disease.
  • The precise mechanisms driving selective neuronal death in these conditions remain largely unknown.
  • PolyQ diseases are characterized by the expansion of CAG repeats in specific genes, leading to protein aggregation and cellular dysfunction.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying selective neuronal death in polyQ neurodegenerative disorders.
  • To identify novel protein interactions involved in the pathogenesis of Spinocerebellar Ataxia type 1 (SCA1).
  • To elucidate the role of transcriptional machinery components in the context of neurodegeneration.

Main Methods:

  • Co-immunoprecipitation assays to detect protein-protein interactions.
  • Immunohistochemistry to analyze protein localization in cerebellar tissue.
  • Western blotting to assess protein expression levels.
  • Analysis of RNA polymerase II and PQBP-1 interactions in cellular and animal models of SCA1.

Main Results:

  • A direct physical and functional link was established between RNA polymerase II and PQBP-1, a protein enriched in the cerebellum.
  • PQBP-1 was identified as a key mediator influencing the interaction between RNA polymerase II and disease-associated proteins in SCA1.
  • The interaction between RNA polymerase II and PQBP-1 contributes to the selective vulnerability of specific neuronal populations in SCA1.

Conclusions:

  • The findings reveal a novel mechanism involving RNA polymerase II and PQBP-1 that contributes to the selectivity of neuronal death in Spinocerebellar Ataxia type 1.
  • This study provides critical insights into the pathogenesis of polyQ neurodegenerative diseases by linking transcriptional regulation to cell death pathways.
  • Targeting the RNA polymerase II-PQBP-1 interaction may offer a potential therapeutic strategy for SCA1 and related disorders.

Related Experiment Videos